A new study suggests that widely used injectable weight-loss drugs, including semaglutide-based treatments like Ozempic and Wegovy, may contribute to a higher risk of hair loss, particularly among women. The findings, published on MedRxiv—a platform for preliminary research yet to be peer-reviewed—highlight an emerging concern as the use of these drugs continues to rise.
Increased Hair Loss Risk Identified
Researchers in Canada, led by Dr. Mohit Sodhi from the University of British Columbia, analyzed medical records of over 1,900 people prescribed semaglutide and 1,300 taking bupropion-naltrexone (sold as Contrave), an older weight-loss medication. To isolate the effects of semaglutide on hair loss, the study focused solely on individuals using Wegovy for weight management, excluding those with diabetes.
The results revealed that those on semaglutide had a 50% higher risk of developing hair-loss conditions compared to those using Contrave. Women appeared to be at an even greater risk, with the likelihood of hair loss twice as high as that observed in men.
Potential Causes of Hair Loss
The study does not establish a direct cause-and-effect relationship, but researchers have proposed several explanations.
-
Rapid Weight Loss and Physiological Stress
Semaglutide facilitates greater and more rapid weight loss than older medications. Dr. Sodhi explains that this accelerated weight reduction can create significant physiological stress, which may trigger hair loss. -
Nutrient Deficiencies
These drugs suppress appetite, leading to reduced food intake. This can result in nutrient deficiencies, particularly in protein, which is essential for hair growth. Additionally, gastrointestinal side effects such as nausea and vomiting may further limit nutrient absorption.
Weighing the Risks and Benefits
The findings raise important questions about the trade-offs of using semaglutide for weight loss. While the drugs have been praised for their effectiveness in reducing obesity-related health risks, including heart disease and sleep apnea, potential side effects like hair loss may influence a person’s decision to use them.
Dr. Sodhi notes that the significance of this risk depends on individual circumstances. For someone managing diabetes, hair loss might be an acceptable side effect when weighed against the drug’s benefits. However, for individuals using the medication for cosmetic weight loss, the risk could be a bigger concern.
Need for Further Research
As GLP-1 drugs like Ozempic and Wegovy become more prevalent, studies like this one underscore the need for a deeper understanding of their long-term effects. Dr. Sodhi emphasizes that awareness of potential side effects is crucial. If people don’t know the potential risks,” he warns, “they may be getting into something they didn’t sign up for.
With demand for weight-loss medications surging, continued research will be essential in helping patients and healthcare providers make informed decisions about their use.
